UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

[ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2010

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________________To ______________________

Commission file number: 333-161157

NEUROKINE PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

Nevada	N/A
(State or other jurisdiction of incorporation or	(I.R.S. Employer Identification No.)
organization)
1275 West 6th Ave. Vancouver, British Columbia,
Canada V6H 1A6	604.805.7783
(Address of principal executive offices) (Zip Code)	(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was require to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [ x ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
[ ] Yes [ ] No

APPLICABLE ONLY TO CORPORATE ISSUERS

As of June 21, 2010 the registrant’s outstanding common stock consisted of <>28,021,618 shares.

Table of Contents

PART I - FINANCIAL INFORMATION			3
	ITEM 1.	FINANCIAL STATEMENTS	3
	ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION	14
	ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.	18
	ITEM 4.	CONTROLS AND PROCEDURES	18
PART II. OTHER INFORMATION			19
	ITEM 1.	LEGAL PROCEEDINGS	19
	ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCCEDS	19
	ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	19
	ITEM 4.	[REMOVED AND RESERVED]	19
	ITEM 5.	OTHER INFORMATION	19
	ITEM 6.	EXHIBITS.	19
SIGNATURES			20

2

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The unaudited interim financial statements of Neurokine Pharmaceuticals Inc. (the “Company”, “Neurokine”, “we”, “our”, “us”) follow. All currency references in this report are to U.S. dollars unless otherwise noted.

3

NEUROKINE PHARMACEUTICALS
INC.

Financial Statements

(Expressed in Canadian dollars)

Three Months Ended April 30, 2010

4

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Balance Sheets

(Expressed in Canadian dollars)

	April 30,		January 31,
	2010		2010
	$		$
	(unaudited)
Assets
Current Assets
Cash	6,198		18,979
Total Assets	6,198		18,979
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued liabilities	17,678		9,809
Loan payable (Note 3)	5,000		5,000
Total Current Liabilities	22,678		14,809
Stockholders’ Equity (Deficit)
Common Stock: 200,000,000 shares authorized, without par value    23,973,618 and 23,829,618 shares issued and outstanding	855,284		826,484
Common stock subscribed (Note 5)	9,600		32,000
Additional paid-in capital	42,159		42,159
Accumulated deficit during the development stage	(923,523	)	(896,473	)
Total Stockholders’ Equity (Deficit)	(16,480	)	4,170
Total Liabilities and Stockholders’ Equity (Deficit)	6,198		18,979

Nature of Operations and Continuance of Business (Note 1)

(The accompanying notes are an integral part of these financial statements)

5

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Statements of Operations

(Expressed in Canadian dollars)

(unaudited)

					Accumulated
					from June 10,
	For the Three		For the Three		2002 (Date of
	Months Ended		Months Ended		Inception) to April
	April 30,		April 30,		30,
	2010		2009		2010
	$		$		$
Revenue	–		–		–
Expenses
Foreign exchange loss	182		–		4,318
General and administrative	10,630		3,823		86,672
Management fees (Note 5)	6,400		–		52,900
Professional fees	9,838		8,980		54,959
Research and development	–		–		224,674
Royalty and license fee	–		–		500,000
Total Expenses	27,050		12,803		923,523
Net Loss	(27,050	)	(12,803	)	(923,523	)
Net loss per share, basic and diluted	–		–
Weighted average shares outstanding	23,878,157		23,740,418

(The accompanying notes are an integral part of these financial statements)

6

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Statements of Cash Flows

(Expressed in Canadian dollars)

(unaudited)

					Accumulated
					from June 10,
	For the Three		For the Three		2002 (Date of
	Months Ended		Months Ended		Inception) to
	April 30,		April 30,		April 30,
	2010		2009		2010
	$		$		$
Operating Activities
Net loss for the period	(27,050	)	(12,803	)	(923,523	)
Adjustments to reconcile net loss to net cash used in operating activities:
Shares issuable for management fees	6,400		–		38,400
Shares issued for royalties	–		–		500,000
Shares issued for services	–		–		60,000
Stock-based compensation	–		–		42,159
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	7,869		–		17,678
Net Cash Used In Operating Activities	(12,781	)	(12,803	)	(265,286	)
Financing Activities
Proceeds from issuance of common shares	–		–		82,896
Shares subscriptions received	–		–		183,588
Proceeds from loans received	–		5,000		5,000
Net Cash Provided by Financing Activities	–		5,000		271,484
Increase (Decrease) in Cash	(12,781	)	(7,803	)	6,198
Cash – Beginning of Period	18,979		29,724		–
Cash – End of Period	6,198		21,921		6,198
Supplemental disclosures:
Interest paid	–		–		–
Income tax paid	–		–		–

(The accompanying notes are an integral part of these financial statements)

7

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Notes to the Financial Statements

Three Months Ended April 30, 2010

(Expressed in Canadian dollars)

(unaudited)

1. Nature of Operations and Continuance of Business

Neurokine Pharmaceuticals Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on June 10, 2002. The Company is a development stage company, as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, “Development Stage Entities” and is in the business of developing and commercializing new uses for existing prescription drugs for diseases mediated by acute and chronic inflammatory reactions as well as developing proprietary encapsulation technology in the treatment of neurodegenerative diseases.

These financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at April 30, 2010, the Company has not earned any revenue, and has an accumulated deficit of $923,523. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

2.	Significant Accounting Policies
	(a)	Basis of Presentation
		The financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in Canadian dollars. The Company’s fiscal year-end is January 31.
	(b)	Interim Financial Statements
		These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended January 31, 2010.
		The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at April 30, 2010, and the results of its operations and cash flows for the three month period ended April 30, 2010 and 2009. The results of operations for the period ended April 30, 2010 are not necessarily indicative of the results to be expected for future quarters or the full year.

8

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Notes to the Financial Statements

Three Months Ended April 30, 2010

(Expressed in Canadian dollars)

(unaudited)

2.	Significant Accounting Policies (continued)
	(c)	Use of Estimates
		The preparation of these financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the fair value on share-based payments, and deferred income tax valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
	(d)	Cash and Cash Equivalents
		The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.
	(e)	Research and Development
		Research costs are expensed in the period that they are incurred. Development costs are expensed in the period that they are incurred unless the Company believes a development project meets generally accepted criteria for deferral and amortization.
	(f)	Stock-Based Compensation
		The Company records stock-based compensation in accordance with ASC 718, “Compensation – Stock Based Compensation” using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued.
	(g)	Basic and Diluted Net Loss Per Share
		The Company computes net loss per share in accordance with ASC 260, “Earnings per Share“. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive.

9

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Notes to the Financial Statements

Three Months Ended April 30, 2010

(Expressed in Canadian dollars)

(unaudited)

2. Significant Accounting Policies (continued)

(h)	Foreign Currency Translation
	The Company’s functional currency and its reporting currency is the Canadian dollar and foreign currency transactions are primarily undertaken in United States dollars. The financial statements of the Company are translated to Canadian dollars in accordance with ASC 830, “Foreign Currency Translation Matters” using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.
(i)	Comprehensive Loss
	ASC 220, “Comprehensive Income” establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at April 30, 2010 and January 31, 2009, the Company had no items representing comprehensive loss.
(j)	Financial Instruments and Fair Value Measures
	ASC 820, Fair Value Measurements, and ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 and 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 and 825 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities, and loan payable. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

10

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Notes to the Financial Statements

Three Months Ended April 30, 2010

(Expressed in Canadian dollars)

(unaudited)

2.	Significant Accounting Policies (continued)
	(k)	Recent Accounting Pronouncements
		In January 2010, the FASB issued an amendment to ASC 505, Equity, where entities that declare dividends to shareholders that may be paid in cash or shares at the election of the shareholders are considered to be a share issuance that is reflected prospectively in EPS, and is not accounted for as a stock dividend. This standard is effective for interim and annual periods ending on or after December 15, 2009 and is to be applied on a retrospective basis. The adoption of this standard is not expected to have a significant impact on the Company’s financial statements.
		In October 2009, the FASB issued an amendment to the accounting standards related to certain revenue arrangements that include software elements. This standard clarifies the existing accounting guidance such that tangible products that contain both software and non-software components that function together to deliver the product’s essential functionality, shall be excluded from the scope of the software revenue recognition accounting standards. Accordingly, sales of these products may fall within the scope of other revenue recognition standards or may now be within the scope of this standard and may require an allocation of the arrangement consideration for each element of the arrangement. This standard, for which the Company is currently assessing the impact, will become effective on January 1, 2011.
		In October 2009, FASB issued an amendment to the accounting standards related to the accounting for revenue in arrangements with multiple deliverables including how the arrangement consideration is allocated among delivered and undelivered items of the arrangement. Among the amendments, this standard eliminated the use of the residual method for allocating arrangement considerations and requires an entity to allocate the overall consideration to each deliverable based on an estimated selling price of each individual deliverable in the arrangement in the absence of having vendor-specific objective evidence or other third party evidence of fair value of the undelivered items. This standard also provides further guidance on how to determine a separate unit of accounting in a multiple-deliverable revenue arrangement and expands the disclosure requirements about the judgments made in applying the estimated selling price method and how those judgments affect the timing or amount of revenue recognition. This standard, for which the Company is currently assessing the impact, will become effective on January 1, 2011.
		On September 30, 2009, the Company adopted changes issued by FASB to the authoritative hierarchy of GAAP. These changes establish the FASB Accounting Standards Codification (Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. These changes and the Codification itself do not change GAAP. Other than the manner in which new accounting guidance is referenced, the adoption of these changes had no impact on the Company’s financial statements.

11

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Notes to the Financial Statements

Three Months Ended April 30, 2010

(Expressed in Canadian dollars)

(unaudited)

2.	Significant Accounting Policies (continued)
	(k)	Recent Accounting Pronouncements (continued)
		In August 2009, FASB issued an amendment to the accounting standards related to the measurement of liabilities that are recognized or disclosed at fair value on a recurring basis. This standard clarifies how a company should measure the fair value of liabilities and that restrictions preventing the transfer of a liability should not be considered as a factor in the measurement of liabilities within the scope of this standard. This standard is effective for the Company on October 1, 2009. The adoption of this amendment did not have a material effect on the Company’s financial statements.
		Effective June 30, 2009, the Company adopted a new accounting standard issued by the FASB related to the disclosure requirements of the fair value of the financial instruments. This standard expands the disclosure requirements of fair value (including the methods and significant assumptions used to estimate fair value) of certain financial instruments to interim period financial statements that were previously only required to be disclosed in financial statements for annual periods. In accordance with this standard, the disclosure requirements have been applied on a prospective basis and did not have a material impact on the Company’s financial statements.
		In June 2009, the FASB issued guidance now codified as ASC 105, Generally Accepted Accounting Principles as the single source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with U.S. GAAP, aside from those issued by the SEC. ASC 105 does not change current U.S. GAAP, but is intended to simplify user access to all authoritative U.S. GAAP by providing all authoritative literature related to a particular topic in one place. The adoption of ASC 105 did not have a material impact on the Company’s consolidated financial statements, but did eliminate all references to pre-codification standards.
3.	Loan Payable
	On April 1, 2009, the Company entered into a demand loan with a company controlled by a director of the Company for $5,000. Under the terms of the loan, the amount is unsecured, non-interest bearing, and due on demand.
4.	Related Party Transactions
	(a)	During the three months ended April 30, 2010, the Company incurred management fees of $6,400 (2009 - $nil) to management and directors of the Company.
	(b)	As at April 30, 2010, the Company owes $5,000 to a company controlled by a director of the Company, as disclosed in Note 3.
5.	Common Stock
	During the period ended April 30, 2010, the Company authorized the issuance of 32,000 common shares with a value of $6,400 for management fees. On March 31, 2010, the Company issued 144,000 common shares with a fair value of $28,800 for management fees that were previously recorded as common stock subscribed. As at April 30, 2010, the Company has authorized 48,000 common shares with a fair value of $9,600 which has not been issued,

12

NEUROKINE PHARMACEUTICALS INC.

(A Development Stage Company)

Notes to the Financial Statements

Three Months Ended April 30, 2010

(Expressed in Canadian dollars)

(unaudited)

6.	Stock Options
	The following table summarizes the continuity of the Company’s stock options:

			Weighted
		Weighted	average	Aggregate
		average	remaining	intrinsic
	Number	exercise price	contractual life	value
	of options	$	(years)	$
Outstanding and exercisable, January 31, 2009	–	–
Granted	300,000	0.20
Outstanding and exercisable, January 31, 2010 and April 30, 2010	300,000	0.20	0.21	–

Additional information regarding stock options as of April 30, 2010, is as follows:

	Exercise
Number of	Price
Options	$	Expiry Date
300,000	0.20	July 13, 2010
300,000

As of April 30, 2010, the Company had no unrecognized compensation expense relating to unvested options.

7.	Subsequent Events
	On May 3, 2010, the Company issued 48,000 common shares for management fees relating to a management agreement that expired on March 31, 2010. Refer to Note 5.
	On May 28, 2010, the Company issued 4,000,000 common shares at US$0.005 per common share for proceeds of US$20,000.

13

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Forward Looking Statements

This report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues, or other financial items; any statements of the plans, strategies, and objectives of management for future operation; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief; and any statement of assumptions underlying any of the foregoing. Such forward-looking statements are subject to inherent risks and uncertainties, and actual results could differ materially from those anticipated by the forward-looking statements.

These forward-looking statements involve significant risks and uncertainties, including, but not limited to, the following: competition, promotional costs and the risk of declining revenues. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of a number of factors. These forward-looking statements are made as of the date of this filing, and we assume no obligation to update such forward-looking statements. The following discusses our financial condition and results of operations based upon our consolidated financial statements which have been prepared in conformity with accounting principles generally accepted in the United States. It should be read in conjunction with our financial statements and the notes thereto included elsewhere herein.

Results of Operations – Three Months Ended April 30, 2010 and Three Months Ended April 30, 2009

The following summary of our results of operations should be read in conjunction with our financial statements for the quarter ended April 30, 2010, which are included herein.

Our operating results for the three months ended April 30, 2010, for the three months ended April 30, 2009 and the changes between those periods for the respective items are summarized as follows:

	Three Months Ended April 30, 2010	Three Months Ended April 30, 2009	Change Between Three Month Period Ended April 30, 2010 and April 30, 2009
Revenue	$ Nil	$ Nil	$ Nil
Foreign exchange loss (gain) loss	$ 182	$ Nil	$ 182
General and administrative	$ 10,630	$ 3,823	$ 6,807
Management fees	$ 6,400	$ Nil	$ 6,400
Professional fees	$ 9,838	$ 8,980	$ 858
Net (Loss)	$ (27,050)	$ (12,803)	$ 14,247

Our accumulated losses increased to $923,523 as of April 30, 2010. Our financial statements report a net loss of $27,050 for the three month period ended April 30, 2010 compared to a net loss of $12,803 for the three month period ended April 30, 2009. Our losses have increased primarily as a result of increased general and administrative fees and management fees.

Our total current liabilities as of April 30, 2010 were $22,678 as compared to total liabilities of $14,809 as of January 31, 2010. The increase was due to accounts payable and increased liabilities.

Revenue

We have not earned any revenues since our inception and we do not anticipate earning revenues in the upcoming quarter.

14

Liquidity and Financial Condition

Working Capital

		At		At
		April 30,		January 31,
		2010		2010
Current assets	$	6,198		18,979
Current liabilities		22,678		14,809
Working capital (deficit)	$	(16,480	)	4,170

Cash Flows

		At		At
		April 30,		April 30,
		2010		2009
Net cash used in operating activities	$	(12,781	)	(12,803	)
Net cash used in investing activities		Nil		Nil
Net cash provided by financing activities		Nil		5,000
Net increase (decrease) in cash during period	$	(12,781	)	(7,803	)

Operating Activities

Net cash used by operating activities was $12,781 in the three months ended April 30, 2010 compared with net cash used by operating activities of $12,803 in the three months ended April 30, 2009.

Investing Activities

Net cash used in investing activities was $Nil in the three months ended April 30, 2010 compared to net cash used in investing activities of $Nil in the three months ended April 30, 2009.

Financing Activities

Net cash provided by financing activities was $Nil in the three months ended April 30, 2010 compared to $5,000 provided by financing activities in the three months ended April 30, 2009.

We will require additional funds to fund our budgeted expenses over the next 12 months. These funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. There is still no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on his investment in our common stock. Further, we may continue to be unprofitable. We need to raise additional funds in the immediate future in order to proceed with our budgeted expenses.

15

Specifically, we estimate our operating expenses and working capital requirements for the next 12 months to be as follows:

Description		Estimated Expenses
Sales and Marketing Costs
Advertising	$	3,600
Investor Relations	$	60,000
Literature	$	6,000
Conference Attendance	$	21,000
Travel	$	22,000
Entertainment and Promotions	$	2,400
Total Sales and Marketing Costs	$	115,000
General and Administrative Expenses
Professional Fees	$	60,000
Consulting Support	$	30,000
Employee Salaries and Benefits	$	384,000
Office Equipment	$	1,600
Office Supplies	$	1,200
Office and Lab Lease	$	40,000
Telephone, Fax, Cellular, Internet	$	6,000
Vehicles and Transportation	$	14,400
Total General and Administrative Expenses	$	537,200
Clinical Trials
NK-001	$	1,355,000
NK-002	$	500,000
Total Clinical Trials	$	1,855,000

Based on our planned expenditures, we will require additional funds of approximately $2.5MM (a total of $2,507,208 less our negative working capital of approximately $828 as of April 30, 2010) to proceed with our business plan over the next 12. If we secure less than the full amount of financing that we require, we will not be able to carry out our complete business plan and we will be forced to proceed with a scaled back business plan based on our available financial resources.

Inflation

The amounts presented in the financial statements do not provide for the effect of inflation on our operations or financial position. The net operating losses shown would be greater than reported if the effects of inflation were reflected either by charging operations with amounts that represent replacement costs or by using other inflation adjustments.

Off-Balance Sheet Arrangements

As of April 30, 2010 we had no off balance sheet transactions that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

16

Foreign Currency Translation

Our company’s functional currency and our reporting currency is the Canadian dollar and foreign currency transactions are primarily undertaken in United States dollars. The financial statements of our company are translated to Canadian dollars in accordance with ASC 830, Foreign Currency Translation, using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.

Basic and Diluted Net Loss Per Share

Our company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive.

Recent Accounting Pronouncements

In January 2010, the FASB issued an amendment to ASC 505, Equity, where entities that declare dividends to shareholders that may be paid in cash or shares at the election of the shareholders are considered to be a share issuance that is reflected prospectively in EPS, and is not accounted for as a stock dividend. This standard is effective for interim and annual periods ending on or after December 15, 2009 and is to be applied on a retrospective basis. The adoption of this standard is not expected to have a significant impact on our company’s financial statements.

In October 2009, the FASB issued an amendment to the accounting standards related to certain revenue arrangements that include software elements. This standard clarifies the existing accounting guidance such that tangible products that contain both software and non-software components that function together to deliver the product’s essential functionality, shall be excluded from the scope of the software revenue recognition accounting standards. Accordingly, sales of these products may fall within the scope of other revenue recognition standards or may now be within the scope of this standard and may require an allocation of the arrangement consideration for each element of the arrangement. This standard, for which our company is currently assessing the impact, will become effective on January 1, 2011.

In October 2009, FASB issued an amendment to the accounting standards related to the accounting for revenue in arrangements with multiple deliverables including how the arrangement consideration is allocated among delivered and undelivered items of the arrangement. Among the amendments, this standard eliminated the use of the residual method for allocating arrangement considerations and requires an entity to allocate the overall consideration to each deliverable based on an estimated selling price of each individual deliverable in the arrangement in the absence of having vendor-specific objective evidence or other third party evidence of fair value of the undelivered items. This standard also provides further guidance on how to determine a separate unit of accounting in a multiple-deliverable revenue arrangement and expands the disclosure requirements about the judgments made in applying the estimated selling price method and how those judgments affect the timing or amount of revenue recognition. This standard, for which our company is currently assessing the impact, will become effective on January 1, 2011.

On September 30, 2009, our company adopted changes issued by FASB to the authoritative hierarchy of GAAP. These changes establish the FASB Accounting Standards Codification (Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. These changes and the Codification itself do not change GAAP. Other than the manner in which new accounting guidance is referenced, the adoption of these changes had no impact on our company’s financial statements.

17

In August 2009, FASB issued an amendment to the accounting standards related to the measurement of liabilities that are recognized or disclosed at fair value on a recurring basis. This standard clarifies how a company should measure the fair value of liabilities and that restrictions preventing the transfer of a liability should not be considered as a factor in the measurement of liabilities within the scope of this standard. This standard is effective for our company on October 1, 2009. The adoption of this amendment did not have a material effect on our company’s financial statements.

Effective June 30, 2009, our company adopted a new accounting standard issued by the FASB related to the disclosure requirements of the fair value of the financial instruments. This standard expands the disclosure requirements of fair value (including the methods and significant assumptions used to estimate fair value) of certain financial instruments to interim period financial statements that were previously only required to be disclosed in financial statements for annual periods. In accordance with this standard, the disclosure requirements have been applied on a prospective basis and did not have a material impact on our company’s financial statements.

In June 2009, the FASB issued guidance now codified as ASC 105, Generally Accepted Accounting Principles as the single source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with U.S. GAAP, aside from those issued by the SEC. ASC 105 does not change current U.S. GAAP, but is intended to simplify user access to all authoritative U.S. GAAP by providing all authoritative literature related to a particular topic in one place. The adoption of ASC 105 did not have a material impact on our company’s consolidated financial statements, but did eliminate all references to pre-codification standards.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK.

As a “smaller reporting company”, we are not required to provide the information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of April 30, 2010. Based on the evaluation of these disclosure controls and procedures the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective.

Changes in Internal Controls

During the quarter covered by this report there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

18

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCCEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.	[REMOVED AND RESERVED]
ITEM 5.	OTHER INFORMATION

None.

ITEM 6. EXHIBITS.

The following exhibits are included with this quarterly filing:

Exhibit No.	Description
31.1	Sec. 302 Certification of Principal Executive Officer
31.2	Sec. 302 Certification of Principal Financial Officer
32.1	Sec. 906 Certification of Principal Executive Officer
32.2	Sec. 906 Certification of Principal Financial Officer

19

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NEUROKINE PHARMACEUTICALS INC.
	(Registrant)
Dated: June 21, 2010	/s/ Dr. Ahmad Doroudian
	Dr. Ahmad Doroudian
	President, Chief Executive Officer and Director
	(Principal Executive Officer)
Dated: June 21, 2010	/s/ Judson Culter
	Judson Culter
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting
	Officer)

20